CHA
FTXH icon

Carmichael Hill & Associates’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Carmichael Hill & Associates’s Portfolio FTXH Stock Details FTXH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-260
Closed -$6.92K – 783
2023
Q4 		$6.92K Buy
+260
New +$6.55K ﹤0.01% 623

Other funds holding FTXH

SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WFA
WMG Financial Advisors Knoxville, Tennessee $265M AUM 26.03% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VCM
Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Carmichael Hill & Associates's FTXH Position: Q1 2024 in Review

Carmichael Hill & Associates sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q1 2024, closing a stake of 260 shares — an estimated $6.92K sold.

Carmichael Hill & Associates first reported a position in FTXH in Q4 2023 and held it in 1 quarter. The position peaked at $6.92K in Q4 2023. 19 funds tracked by Wall St. Rank hold FTXH as of Q1 2024.

  • Carmichael Hill & Associates reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q1 2024 after selling out during the quarter.
  • Carmichael Hill & Associates sold 260 First Trust Nasdaq Pharmaceuticals ETF shares in Q1 2024, an estimated $6.92K.
  • Carmichael Hill & Associates first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2023 and held it in 1 quarter.
  • Carmichael Hill & Associates's First Trust Nasdaq Pharmaceuticals ETF position peaked at $6.92K in Q4 2023.
  • 19 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q1 2024.

Based on Carmichael Hill & Associates's 13F filing for Q1 2024, filed 24 Apr 2024.